Neuren Pharmaceuticals Updates on Securities Buy-Back Program

An announcement from Neuren Pharmaceuticals Limited ( (AU:NEU) ) is now available.

Neuren Pharmaceuticals Limited has announced an update regarding its ongoing buy-back program, with a total of 3,570,284 securities bought back prior to the previous day and an additional 20,084 securities bought back on the previous day. This buy-back initiative reflects the company’s strategic efforts to manage its capital structure and potentially enhance shareholder value.

The most recent analyst rating on (AU:NEU) stock is a Buy with a A$30.65 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapeutics for neurological disorders. The company is listed on the Australian Securities Exchange under the code NEU and is involved in the research and development of innovative treatments.

YTD Price Performance: 2.96%

Average Trading Volume: 781,892

Technical Sentiment Signal: Hold

Current Market Cap: A$1.64B

For detailed information about NEU stock, go to TipRanks’ Stock Analysis page.